Prior Authorization for Crohn's Disease: An Appeals Guide

Prior authorization for Crohn's disease is your insurer requiring approval before it will pay for a drug or test your gastroenterologist already prescribed, and you have 180 days from a denial notice to file an internal appeal and 4 months after a final denial to request a binding external review (5)(6).

If you are holding a denial letter right now, you are far from alone. In a national survey of 2,281 patients and caregivers run by the Crohn's and Colitis Foundation, 56.2 percent had trouble accessing medication because of their health insurance (2). Prior authorization for Crohn's disease is now routine rather than exceptional, and understanding how it works is the difference between a denial that sticks and one that gets overturned.

Key Takeaways

• In a survey of 2,281 US patients and caregivers, 56.2 percent had problems accessing IBD medication because of insurance, and 16.8 percent waited a month or longer (2).
• Among gastroenterologists reviewing 23 specific IBD denial scenarios, more than 75 percent disagreed with the insurer in 18 of the 23 (3).
• From January 1, 2026, impacted payers must decide standard prior authorization requests within seven calendar days and expedited requests within 72 hours (4).
• The critical caveat: those new CMS deadlines do not apply to prior authorization decisions for drugs, so biologic approvals are not covered (4).
• You have 180 days to file an internal appeal, and 4 months after a final denial to request an external review the insurer must legally accept (5)(6).
• A denial reflects a plan's cost rules, not any failing on your part.

Prior Authorization and Step Therapy: What They Actually Are

Prior authorization is a coverage rule, not a medical opinion. Your insurer requires its own approval before paying for a drug, test, or procedure your gastroenterologist has already decided you need. The prescription is valid. Only payment is in question. Three different processes get bundled under the same label, and knowing which one you face changes how you respond.

Prior authorization vs. step therapy vs. re-authorization

Prior authorization is the initial approval request for something new: a first biologic, an MR enterography, a capsule endoscopy.

Step therapy, also called a fail first policy, requires you to try and fail a cheaper drug before the insurer will cover the one your doctor selected, substituting a formulary tier for clinical reasoning. As we explored in our guide on choosing the best biologic for Crohn's disease, that choice normally rests on disease location, severity, extraintestinal symptoms, and prior response. A forced switch to a cheaper version of the same molecule is a related situation, covered in our biosimilars guide.

Re-authorization is a renewal review of a medication you are already stable on, and it surprises people most because nothing has changed. It is also an enormous share of the workload: in a 2021 national survey of gastroenterology providers, roughly half of the requests and appeals practices handled in a given week were refills for drugs patients were already taking (1).

One more term worth knowing: the peer-to-peer review, a phone call between your prescriber and a reviewing physician at the insurance company. It is often the fastest route to an overturn, but scheduling it is a common source of multiday delay (3).

How Often This Happens to Crohn's Patients

Access problems are the norm rather than the exception. In the Crohn's and Colitis Foundation's survey of 2,281 US patients and caregivers, 56.2 percent reported trouble accessing medication because of their health insurance (2). This is a systemic feature of how IBD care is paid for.

What the Crohn's and Colitis Foundation survey found

The numbers are the clearest evidence that delay itself causes harm:

• 24.8 percent of medicated respondents faced a step therapy mandate, and 85.4 percent of that group reported adverse health outcomes (2).
• 16.8 percent waited a month or longer for insurance approval (2).
• 69.4 percent reported adverse health events when they could not get, or were delayed in getting, their IBD medication (2).
• 24.4 percent had trouble paying or could not pay IBD-related medical bills, and 41.1 percent reported one or more financial barriers or trade-offs in the prior 12 months (2).

What gastroenterologists report

Providers see the same pattern from the other side of the desk. In a 2021 national survey of 156 gastroenterology providers, 54.4 percent reported patients experiencing serious adverse events due to prior-authorization-related delays, and 59.5 percent of practices had hired dedicated staff purely to process these requests (1). That second number is quietly useful: many GI offices now have a specific person for this, and asking for them by role is a reasonable first move.

Why Denials Often Do Not Reflect Medical Evidence

A denial is a statement about a plan's coverage criteria, not a verdict on whether your treatment is appropriate. When researchers presented 84 gastroenterologists with 23 denied IBD treatment scenarios, more than 75 percent of the specialists disagreed with the denial in 18 of the 23, and more than 50 percent disagreed in 22 of 23 (3).

Where specialists and insurers disagree most

Disagreements cluster in recognizable situations (3):

1. Dose escalation after loss of response, when a drug worked and then stopped.
2. Dose changes guided by therapeutic drug monitoring, where drug levels or antibody results point to a specific adjustment.
3. First-line use of certain biologics, when your gastroenterologist wants to start with a particular agent rather than step through others.
4. Re-authorization of a stable dose, where nothing has changed and the renewal is questioned anyway.

If your denial falls into one of these buckets, say so in your appeal and cite the finding: specialists overwhelmingly disagreed with denials in this exact category of scenario (3). That moves the appeal from a matter of preference to a documented conflict with published specialist consensus.

What Changed in 2026 and What Did Not

Beginning January 1, 2026, impacted payers must decide expedited prior authorization requests within 72 hours and standard requests within seven calendar days, must give a specific reason for any denial, and must publicly report prior authorization metrics each year, with the first posting due March 31, 2026 (4). Real progress, and narrower than most headlines suggested.

The CMS Interoperability and Prior Authorization Final Rule

The rule, CMS-0057-F, applies to Medicare Advantage organizations, state Medicaid and CHIP fee-for-service programs, Medicaid and CHIP managed care plans, and Qualified Health Plan issuers on the Federally Facilitated Exchanges, with those QHP issuers excluded from the timeframe requirement specifically (4). If you have employer-sponsored coverage, the rule does not reach your plan at all.

The drug carve-out that matters most for Crohn's

Here is the part that deserves to be said without softening: the timeframe requirements and the specific-denial-reason requirement do not apply to prior authorization decisions for drugs (4). The seven-day and 72-hour clocks do not cover your ustekinumab, risankizumab, vedolizumab, infliximab, adalimumab, or upadacitinib approval.

What the rule may genuinely speed up is the diagnostic side: MR enterography, CT enterography, colonoscopy, capsule studies. Those are procedures, not drugs, and on an impacted plan they now run on a deadline. Your biologic still runs on your plan's own clock.

For readers outside the United States, the CMS rule and the federal appeal timelines described here are US-specific, and your own health authority will have an equivalent process. The strategy of documenting everything and escalating in writing still applies.

Your Appeal Rights: Internal Appeal and External Review

Two escalation paths run in sequence. You have 180 days from the date of your denial notice to file an internal appeal with your insurer, and if that fails, 4 months from the final denial notice to request an independent external review (5)(6). These are legal deadlines, so calendar them the day the letter arrives.

Filing the internal appeal

An internal appeal is a full review of your denial by the insurer itself, with defined timelines (5):

• 30 days for a service you have not yet received.
• 60 days for care you have already received.
• For urgent cases, a final decision must come as quickly as your medical condition requires, and within 4 business days at the outside.

If a delay would seriously jeopardize your health or your ability to regain maximum function, the request qualifies for the expedited track, and your prescriber can attest to that.

Requesting an independent external review

If the internal appeal fails, an external review moves the decision out of the insurer's hands. An independent organization evaluates your case, and the insurer is required by law to accept the reviewer's decision (6). Cost is minimal by design: free through the HHS-administered federal process, and no more than 25 dollars through a state or independent review organization process (6). For urgent situations you can request external review without finishing all internal appeals, and an expedited decision comes within 72 hours or less (6).

Practical Steps: Building a Request That Is Harder to Deny

Because denials cluster in predictable categories (3), the documentation that answers those objections can be assembled in advance rather than scrambled together afterward. Start by asking your GI office who handles prior authorizations, since many practices now have dedicated staff for exactly this work (1).

What to gather before the request goes in

Documentation that strengthens a request:

• Objective disease activity: fecal calprotectin, CRP, imaging, endoscopy reports. Symptoms alone are easy for a reviewer to discount; measured inflammation is not.
• Documented prior therapy failures with dates, doses, duration, and why each was stopped. Step therapy appeals often turn entirely on whether this history is in the chart in writing.
• Drug level and antibody results if dose escalation or interval shortening is the issue.
• The specific clinical guideline supporting the request, named by your prescriber.

Scripts and timing

Keep a written log of every call: date, time, representative name, reference number, and what you were told. You will need it for the appeal and any external review filing, and it is far easier to build as you go than to reconstruct later. Three requests worth making explicitly:

• A written denial letter stating the specific reason.
• The plan's clinical criteria used to make the decision. Reading it often reveals exactly which box was considered unchecked.
• A peer-to-peer review, with your prescriber citing the specific guideline supporting the request during that call (3).

While you wait, ask about bridge options. Many manufacturers run patient assistance programs that supply medication during a coverage gap, and a shorter supply can sometimes be authorized to avoid missing a dose. Our guide to financial planning with Crohn's disease covers copay assistance and the longer-term cost picture.

When it starts to feel personal

The survey data makes something plain: this process affects work, school, finances, and health outcomes for a large share of us (2). A denial is a cost-control decision made by someone who has not examined you, in a system where specialists disagree with the majority of these decisions when asked (3). If that dynamic feels familiar elsewhere in your care, our article on medical gaslighting and self-advocacy may help.

Practical takeaway: write down the denial date, calendar the 180-day internal appeal deadline, ask for the written reason and the clinical criteria, request a peer-to-peer, and ask about bridge supply in the meantime. Those five actions cover most of what you control.

Frequently Asked Questions

How long does an insurance appeal for a Crohn's biologic usually take?

For a standard internal appeal, your insurer must decide within 30 days if you have not yet received the service, or 60 days if you already received the care (5). Urgent appeals must be decided as quickly as your condition requires, and within 4 business days at the outside (5). External review adds its own timeline, with expedited decisions within 72 hours (6).

Does the 2026 CMS prior authorization rule apply to my biologic?

No. The rule's timeframe requirements and specific-denial-reason requirement explicitly do not apply to prior authorization decisions for drugs (4). It may speed up approvals for procedures and imaging such as MR enterography or colonoscopy if you are on an impacted plan, but biologic approvals still follow your plan's own process and timing.

Can my insurer force me to fail a cheaper drug first?

Step therapy, or fail first, is a common insurer policy, and 24.8 percent of medicated respondents in the Crohn's and Colitis Foundation survey faced one (2). Many US states have step therapy override laws with medical exception pathways, though rules vary by state and plan type. Ask your GI office to file a step therapy exception citing your clinical circumstances.

What should I do the day my denial letter arrives?

Note the date on the notice, since the 180-day internal appeal window starts from it (5). Request a written denial with the specific reason, plus the plan's clinical criteria. Contact whoever handles prior authorizations at your GI practice, and ask your prescriber about a peer-to-peer review.

Why was my medication denied when I have been stable on it for years?

Re-authorization reviews of stable therapy are extremely common. In a national gastroenterology provider survey, roughly half of the requests and appeals handled in a given week were refills for drugs patients were already taking (1). Specialists frequently disagree with denials in this category (3), which is worth stating directly in your appeal.

What if I run out of medication while waiting for approval?

Ask your prescriber's office about manufacturer patient assistance or bridge programs, which can supply medication during a coverage gap, and about a shorter supply to avoid missing a dose. Also ask whether your situation qualifies for an expedited appeal, since urgent requests carry much shorter deadlines (5)(6).

References

1. Shah ED, Amann ST, Hobley J, Islam S, Taunk R, Wilson L. 2021 National Survey on Prior Authorization Burden and Its Impact on Gastroenterology Practice. American Journal of Gastroenterology, 2022. View on PubMed Central
2. Jordan AA, Bhat S, Ali T, et al. Healthcare Access for Patients With Inflammatory Bowel Disease in the United States: A Survey by the Crohn's and Colitis Foundation. Inflammatory Bowel Diseases, 2025;31(7):1819-1832. Read study
3. Naritsin A, Mehta N, Pellish R. Discordance Between Inflammatory Bowel Disease Specialists and Insurance Authorization Denials: A Survey of Specific Inflammatory Bowel Disease Treatment Scenarios. Crohn's and Colitis 360, 2024;6(1):otad082. Read study
4. Centers for Medicare and Medicaid Services. CMS Interoperability and Prior Authorization Final Rule CMS-0057-F (Fact Sheet). 2024. Read fact sheet
5. HealthCare.gov, Centers for Medicare and Medicaid Services. Internal Appeals: Appealing a Health Plan Decision. Read article
6. HealthCare.gov, Centers for Medicare and Medicaid Services. External Review: Appealing a Health Plan Decision. Read article